The Montreal Heart Institute (MHI) announced that the COLCORONA clinical trial has provided clinically persuasive results of colchicine’s efficacy to treat COVID-19. Read the MHI announcement, Colchicine reduces the risk of COVID-19-related complications.
Ten months ago, to support MHI’s COLCORONA clinical trials, CGI teams worked tirelessly to quickly build the digital onboarding and monitoring platform that helped individuals securely register for this clinical study. (Read the story: CGI helps Montreal Heart Institute find potential treatment for COVID-19.)
CGI congratulates MHI on its innovative research that will have a significant positive impact on public health and reduce the suffering of millions of COVID-19 patients.
